Last updated: May 25, 2026
Brixadi (buprenorphine) Supplier Landscape: Who Makes the Drug, Filings, and Key Upstream Inputs
Brixadi (buprenorphine extended-release) is supplied in the US market by Alkermes, Inc. as the marketing authorization holder for FDA drug product approvals. The upstream manufacturing and input supply chain involves contract manufacturers and specialized suppliers supporting sterile injectable processes, drug substance handling, and controlled substance logistics, but public “supplier-of-record” detail is generally not disclosed in a way that supports a complete list of all upstream vendors.
Who supplies Brixadi (buprenorphine) in the US?
Brixadi is marketed in the US under Alkermes, Inc. ownership of the FDA approval and commercial packaging distribution.
- Brand/active: Brixadi (buprenorphine extended-release)
- Applicant/marketing authorization holder (FDA NDA/label entity): Alkermes, Inc.
- Drug class: Opioid use disorder (buprenorphine long-acting injection)
Supplier-of-record in regulated marketing terms: Alkermes for commercial supply, with manufacturing typically performed by contract manufacturing organizations under Alkermes quality systems.
Which manufacturers make Brixadi drug product (injection) for Alkermes?
Brixadi is manufactured as a long-acting injectable. For this dosage form, the drug product supply chain is usually split into:
- Drug substance production (buprenorphine, then formulation-ready intermediates)
- Sterile drug product manufacturing (suspension/implant-form technology depends on product design)
- Packaging and labeling
- Distribution under controlled-substance requirements
Public sources typically list:
- Manufacturing sites (for drug product and, separately, drug substance) as FDA-registered locations, and/or
- Facilities named on labeling and FDA review documentation.
For Brixadi specifically, the complete facility roster and the identity of each upstream supplier beyond the facility-level are not consistently disclosed in public marketing materials.
What do you get from FDA labeling and registration disclosures?
FDA labels and related listings commonly identify:
- Manufacturing site addresses (facility-level)
- Labeler/distributor entity
- Controlled substance schedule handling requirements
- Storage and handling
These can support “who makes it” at the facility level, but not a full list of “who supplies every input excipient/raw material.”
What upstream raw-material suppliers support Brixadi manufacturing?
For a buprenorphine long-acting injectable, the most supplier-sensitive upstream categories usually include:
- Buprenorphine drug substance (high-purity API grade)
- Sterile manufacturing excipients and formulation components for the extended-release matrix
- Sterile fill-finish components (syringes/needles, stoppers, vial components, or prefilled-device parts depending on presentation)
- Container-closure systems compatible with controlled-release formulation stability
- Lyophilization/sterile processing consumables if used in the manufacturing route
- Cold-chain and GDP-capable logistics partners for controlled substances
Public disclosures often stop at the facility or quality-controlled supplier category; vendor-by-vendor lists are typically contract-protected.
Does Brixadi have multiple strengths or presentations that require different suppliers?
Long-acting buprenorphine products often include multiple dosing strengths and sometimes different needle or delivery configurations. If Brixadi has more than one strength (and/or presentation), the supplier network commonly differs at:
- Fill-finish components matched to each configuration
- Packaging and labeling line formats
- Manufacturing batches under distinct campaign schedules
At the vendor level, the raw material suppliers may stay the same while packaging/assembly suppliers differ by presentation.
How can you identify the real Brixadi supplier list (practical approach)?
The most reliable public pathway to a “supplier list” for a branded injectable is:
- FDA label manufacturing information (drug product and drug substance sites, where listed)
- FDA drug registration databases (facility-level manufacturing data, labeler identity)
- Orange Book and approval history (brand manufacturing references)
- Litigation or CMO disclosure documents (only when surfaced in filings)
This typically yields:
- The site(s) that make Brixadi
- The entity responsible for the NDA/product label
It usually does not yield a complete public roster of every upstream input supplier.
What supplier disclosures are typically missing for Brixadi?
Common gaps in public sources for “supplier of record” claims:
- API supplier identity beyond the API manufacturer site name
- Excipients and extended-release system component suppliers
- Device component OEM identities (unless explicitly named)
- Fill-finish consumables and sterile component vendor identities
- Contracted packaging house identities
For controlled-substance injectables, those details are often contract-controlled.
Key Takeaways
- Alkermes, Inc. is the commercial and regulatory holder for Brixadi supply into the US market.
- The drug product manufacturing is performed at registered facility level sites under Alkermes’ quality system, but public sources generally do not provide a complete vendor-by-vendor upstream supplier roster.
- A true supplier list is typically reconstructible at the facility level via FDA label/registration disclosures, with upstream raw-material and device component suppliers mostly contract-protected.
FAQs
Who is the labeler and distributor for Brixadi?
The labeler/distributor entity for Brixadi is Alkermes, Inc. (as reflected in FDA labeling and product listings).
Are Brixadi manufacturing facilities publicly listed?
Yes, at least at facility level where FDA labeling and registrations disclose manufacturing site information.
Can you name the API supplier for Brixadi from public sources?
Publicly accessible data often identifies the API manufacturing site, but not always the full contractual vendor chain.
Do different Brixadi strengths use different packaging suppliers?
Different strengths/presentations usually require different packaging and device component configurations, so fill-finish and packaging suppliers can vary even if API sourcing is shared.
Where do you find Brixadi’s most reliable supplier information?
The most reliable starting points are FDA label manufacturing sections and FDA facility registration disclosures.
References (APA)
- U.S. Food and Drug Administration. Brixadi (buprenorphine extended-release) prescribing information and FDA product listings (label and manufacturing/distribution information).
